Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
4.340
+0.030 (0.70%)
Aug 12, 2026, 3:50 PM EDT - Market open
Larimar Therapeutics Employees
Larimar Therapeutics had 71 employees as of December 31, 2025. The number of employees increased by 6 or 9.23% compared to the previous year.
Employees
71
Change (1Y)
6
Growth (1Y)
9.23%
Revenue / Employee
n/a
Profits / Employee
-$2,431,056
Market Cap
453.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 71 | 6 | 9.23% |
| Dec 31, 2024 | 65 | 23 | 54.76% |
| Dec 31, 2023 | 42 | 16 | 61.54% |
| Dec 31, 2022 | 26 | -5 | -16.13% |
| Dec 31, 2021 | 31 | 3 | 10.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Abeona Therapeutics | 226 |
| Sutro Biopharma | 133 |
| Enanta Pharmaceuticals | 120 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Upstream Bio | 75 |
| Atea Pharmaceuticals | 55 |
| Eupraxia Pharmaceuticals | 49 |
LRMR News
- 7 days ago - Larimar Therapeutics price target lowered to $11 from $12 at Wedbush - TheFly
- 8 days ago - Larimar Therapeutics reports Q2 EPS (30c), consensus (38c) - TheFly
- 8 days ago - Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - GlobeNewsWire
- 8 days ago - Larimar Therapeutics Earnings release: Q2 2026 - Filings
- 8 days ago - Larimar Therapeutics Quarterly report: Q2 2026 - Filings
- 9 days ago - Larimar Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Larimar Therapeutics director buys $167K in common stock - TheFly
- 5 weeks ago - Larimar Therapeutics assumed with a Buy at H.C. Wainwright - TheFly